Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 16/20 | 0.43 |
| ▸ | DDB1 | Q16531 | 5/20 | 0.35 |
| ▸ | GSPT1 | P15170 | 2/20 | 0.35 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.35 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.35 |
| ▸ | STAT3 | P40763 | 1/20 | 0.35 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.33 |
| ▸ | RARA | P10276 | 1/20 | 0.32 |
| ▸ | RARB | P10826 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31476885 | 0.85 | CD274 (0.39) | CRBNDDB1STAT3CD274 | |
| SCHEMBL27354577 | 0.80 | PPARA (0.37) | RARARARB | |
| SCHEMBL30696752 | 0.80 | CRBN (0.39) | CRBNDDB1GSPT1STAT3 | |
| SCHEMBL22297613 | 0.76 | CRBN (0.56) | CRBNDDB1GSPT1 | |
| SCHEMBL27356799 | 0.75 | CRBN (0.37) | CRBNDDB1GSPT1STAT3 | |
| SCHEMBL27354578 | 0.74 | PPARA (0.36) | RARARARB | |
| SCHEMBL31476929 | 0.67 | ALDH1A1 (0.39) | CD274RARARARB | |
| SCHEMBL20046847 | 0.66 | CRBN (0.44) | CRBNDDB1CD274 | |
| SCHEMBL4388041 | 0.66 | CRBN (0.56) | CRBNDDB1 | |
| SCHEMBL4388040 | 0.66 | CRBN (0.56) | CRBNDDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4543439-A2 | NRF2 PROTEIN DEGRADERS | Ganymede Oncology, Inc. (US) | 2025-04-30 | — | — | EP | disclosed |
| CN-119730847-A | NRF2 protein degradation agent | 盖尼米德肿瘤学股份有限公司 | 2025-03-28 | — | — | CN | disclosed |
| WO-2024006742-A2 | NRF2 PROTEIN DEGRADERS | DRACEN PHARMACEUTICALS, INC. (US) | 2024-01-04 | — | — | WO | disclosed |
| WO-2024006742-A2 | NRF2 PROTEIN DEGRADERS | DRACEN PHARMACEUTICALS, INC. (US) | 2024-01-04 | — | — | WO | disclosed |